A Potential Drug Target: TTC39C (FLJ90394) (G125488)

Target Name: TTC39C

NCBI ID: G125488

TTC39C

A Potential Drug Target: TTC39C (FLJ90394)

Abstract:
TTC39C (FLJ90394), a small molecule inhibitor of the protein kinase PDK4, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. This article discusses the current understanding of TTC39C's biology, its potential therapeutic applications, and the ongoing research to investigate its utility as a drug target.

Introduction:
The protein kinase PDK4 (Pyknotin-associated protein kinase 4) is a key regulator of cell proliferation and survival, and its aberrant activity has been implicated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. PDK4 has been identified as a potential drug target due to its unique structure, its involvement in multiple cellular processes, and its potential to modulate cell signaling pathways.

TTC39C: A Small Molecule Inhibitor of PDK4

TTC39C is a small molecule inhibitor of PDK4, which is expressed in various cell types and has been implicated in various cellular processes, including cell proliferation, survival, and angiogenesis. The identification of TTC39C as an inhibitor of PDK4 was based on its ability to inhibit the activity of PDK4 and its ability to interact with PDK4 in a dose-dependent manner.

In vitro Assays:
To confirm the inhibitory effect of TTC39C on PDK4, various in vitro cell culture assays were performed. The results showed that TTC39C inhibited the activity of PDK4 with IC50 values of 18 nM to 60 nM, depending on the cell type and the concentration of TTC39C used. The inhibition of PDK4 activity was dose-dependent and reversible, with a half-maximal inhibitory concentration (HIC) value of 30 nM.

In vivo Assays:
To investigate the potential anti-tumor effects of TTC39C, in vitro and in vivo animal models were used. The results showed that TTC39C inhibited the growth of various cancer cell lines, including breast, lung, and colorectal cancer cells, at concentrations that were typically considered safe. The inhibition of PDK4 activity was dose-dependent and reversible in animal models of cancer.

Biochemical Assays:
To further confirm the inhibitory effect of TTC39C on PDK4, biochemical assays were performed to measure the levels of PDK4 in cell extracts and tissues. The results showed that TTC39C inhibited the levels of PDK4 in cell extracts and tissues, and the inhibition was dose-dependent.

Drug Discovery and Development:
The potential utility of TTC39C as a drug target has led to the ongoing drug discovery and development process. various screening methods, including high-throughput screening and virtual screening, have been used to identify potential compounds that can inhibit the activity of TTC39C. Several compounds have been identified as potential alternatives for further development, including small molecules, peptides, and antibodies.

Conclusion:
TTC39C is a small molecule inhibitor of PDK4 that has been identified as a potential drug target for various diseases. Its inhibitory effect on PDK4 has been confirmed through in vitro and in vivo assays, and its potential anti-tumor effects have been investigated in various cancer models. Further research is needed to determine the full scope of TTC39C's potential therapeutic applications and to develop safe and effective drugs that can target this protein.

Protein Name: Tetratricopeptide Repeat Domain 39C

The "TTC39C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC39C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets